Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06770452 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment target: 32 to 133 Eligibility criteria expanded, about 14 words · Study arms: 1 to 5v3 Show 2 more changesShow less
    • Eligibility criteria expanded, about 14 words
    • Study arms: 1 to 5

    See this version in full on ClinicalTrials.gov ↗

  2. Trial status: Not Yet Recruiting to Recruiting Study sites: 1 to 2 · Start date changed from estimate of Feb 1, 2025 to Mar 25, 2025v2 Show 2 more changesShow less
    • Study sites: 1 to 2
    • Start date changed from estimate of Feb 1, 2025 to Mar 25, 2025
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a single-arm phase II clinical study to include 32 patients with advanced pancreatic cancer with KRAS G12D mutation to evaluate the effectiveness of HRS-4642 combined with nitutuzumab and AG for first-line treatment of advanced pancreatic cancer.
Trial Details
NCT Number NCT06770452
Lead Sponsor Zhejiang University
Conditions Metastatic Pancreatic Carcinoma
Enrollment 133 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov